On Friday, Quantum Corp (NYSE:QTM)’s shares declined -6.12% to $0.930.
Quantum International Income Corp. (QTM), declared that it has retained LodeRock Advisors Inc., for planned investor relations and capital markets communications services
Under the terms of the agreement, Quantum International will pay LodeRock a monthly fee of CAD $10,000 for select planned communication services. Neither LodeRock, nor any of its executives have an ownership interest, directly or indirectly, in Quantum International or its securities, and Quantum International has not granted LodeRock or its executives any right to acquire any such interests.
Quantum Corporation provides scale-out storage, archive, and data protection solutions for small businesses to major enterprises in the Americas, Europe, and the Asia Pacific. Its scale-out storage portfolio comprises StorNext software, appliances and full systems called StorNext Pro Solutions, in addition to Lattus extended online storage and Q-Cloud Archive services.
Trinity Industries Inc (NYSE:TRN)’s shares dropped -4.75% to $26.49.
Trinity Industries, Inc. (TRN) has declared a quarterly dividend of 11 cents per share on its $0.01 par value common stock. The quarterly cash dividend, representing Trinity’s 206th successively paid dividend, is payable October 30, 2015 to stockholders of record on October 15, 2015.
Trinity Industries, Inc. provides various products and services for the energy, transportation, chemical, and construction sectors in the United States and internationally. Its Rail Group segment offers railcars, counting autorack, box, covered hopper, gondola, intermodal, tank, and open hopper cars; and couplers, axles, and other equipment, in addition to railcar maintenance services. This segment serves railroads, leasing companies, and industrial shippers of various products.
At the end of Friday’s trade, Invesco Mortgage Capital Inc (NYSE:IVR)‘s shares dipped -0.37% to $13.56.
Invesco Mortgage Capital Inc. (IVR) declared that its Board of Directors declared quarterly dividends on shares of its common stock and Series A and Series B preferred stock.
Common Stock Dividend
The Company’s Board of Directors recently declared a cash dividend of $0.40 per share of common stock for the third quarter of 2015. The dividend will be paid on October 27, 2015 to stockholders of record on September 28, 2015, with an ex-dividend date of September 24, 2015.
Series A Preferred Stock Dividend
The Board of Directors declared a quarterly cash dividend on its 7.75% Series A Preferred Stock of $0.4844 per share. The dividend will be paid on October 26, 2015 to stockholders of record on October 1, 2015.
Invesco Ltd. is a publicly owned investment manager. The firm provides its services to retail clients, institutional clients, high-net worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds. It manages separate client focused equity, balanced, and fixed income portfolios.
Kite Pharma Inc (NASDAQ:KITE), ended its Friday’s trading session with 3.13% gain, and closed at $65.94.
Kite Pharma, Inc. (Kite) (KITE) declared that Dr. Franz B. Humer, the former Chairman and Chief Executive of Roche Holding Ltd., has been designated to the Company’s Board of Directors.
Dr. Humer began his career in the pharmaceutical industry in 1973, joining Schering Plough Corporation where he held various General Administration positions in Latin America and Europe. After leaving Schering Plough, he joined the Board of Glaxo Holdings plc and progressed to be responsible for research, business development, manufacturing, commercial strategy, and all non-US operations for 13 years. Subsequent to this, Dr. Humer served as Head of Pharmaceuticals and then as Chief Operating Officer of F. Hoffmann-La Roche Ltd., preceding to his taking the helm as CEO at Roche Group (1998-2001) and then Chairman and CEO (2001-2008). His tenure as Chairman of Roche Holding Ltd. extended from 2008 to 2014.
He is also Chairman of Diageo plc, an Independent Director with Citigroup Inc., Chugai Pharmaceuticals Ltd. (Japan), Bial Pharmaceuticals (Portugal), WISeKey (Cyber Security Company, Switzerland) and a member of the International Advisory Board of Allianz SE.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
